Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 936 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Conditions
Obstructive Sleep Apnea
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
Interventions
Twice daily enoxaparin prophylaxis, Real time dose adjustment
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Conditions
Covid19, SARS-CoV Infection
Interventions
Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo, Resveratrol Placebo
Dietary Supplement
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Asthma
Interventions
TEV-48574, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 47 more
Conditions
Pulmonary Hypertension
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Completed Phase 3 Interventional Results available

Imatinib (QTI571) in Pulmonary Arterial Hypertension

NCT00902174
Conditions
Pulmonary Arterial Hypertension
Interventions
imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
JNJ 49095397, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • St Louis, Missouri • Chapel Hill, North Carolina + 3 more
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational

STRIVE Post-Market Registry Study

NCT04302272
Conditions
Emphysema
Interventions
Spiration Valve System (SVS)
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Phoenix, Arizona • Mountain View, California • Coral Gables, Florida + 11 more
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Conditions
Acute Respiratory Distress Syndrome, ARDS
Interventions
ExoFlo, Intravenous normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Davis, California + 29 more
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Moderate to Severe Asthma
Interventions
3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Airway Redox and Gender Determinants in Severe Asthma

NCT01759186
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
6 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
4
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Conditions
Eosinophilic Asthma
Interventions
Etokimab, Placebo
Biological · Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more
Conditions
Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
Interventions
Fluciclatide Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey